The aim of the present study was to investigate the genotypes of CYP2D6 and SULT1A1 in breast cancer patients with and without tamoxifen treatment in order to validate the relation between the genotype and the benefit from tamoxifen therapy. Here, SULT1A1 is linked to breast carcinoma.